Former Damon Runyon Fellow Gregory J. Hannon, PhD, and colleagues at the Cancer Research UK Cambridge Institute, have developed a new interactive, virtual reality 3D model of breast cancer.  A human tissue sample about the size of a pinhead was used to create the model, which can be magnified to appear several meters across, providing researchers an inside view of how breast cancer cells interact with surrounding healthy tissue. 

The Cancer Research UK Grand Challenge brings together the very best researchers from around the globe to unite their talent, pool resources and crack the biggest questions in cancer research. Matthew L. Meyerson, MD, PhD (Damon Runyon Fellow '95-'98) of the Dana-Farber Cancer Institute, Boston, and Wendy S. Garrett, MD, PhD (Damon Runyon Fellow '06-'09) of the Harvard T.H. Chan School of Public Health, Cambridge, received £20 million to lead an international, multidisciplinary team of researchers focusing on the microbiome and its role in colorectal cancer.

In 2018, William Raveis Real Estate raised an incredible $552,000 for cancer research. They have been a staunch supporter of Damon Runyon, hosting several multi-state fundraising events. At the annual Raveis Ride + Walk, held September 30, 2018, at Calf Pasture Beach in Norwalk, Connecticut, Christy Jefremow bravely shared her story. 

Immunotherapy has saved countless lives but it is not effective for all cancer patients and predicting who should be using this therapy has been difficult. New results from Luc G. Morris, MD (Damon Runyon Clinical Investigator '14-'17) at Memorial Sloan Kettering Cancer Center, New York, and colleagues, now shed light on this dilemma.

Damon Runyon Cancer Research Foundation increases Junior Faculty Grants by 33%. Effective in 2019, the Damon Runyon-Rachleff Innovation and Damon Runyon Clinical Investigator Awards will be increased by 33% for new and current scientists. This investment allows the next generation of elite scientists to conduct work that will lay the foundation for careers filled with untold discoveries that are critical to finding new treatments and cures for patients. 

Recently, the Damon Runyon Bay Area community gathered to celebrate the leadership and generosity of Connie and Bob Lurie and kick off the $1 million Lurie Breakthrough Challenge Fund. “Bob and I are delighted to continue the family tradition of supporting Damon Runyon and are thrilled to be a part of its Bay Area Committee,” Connie Lurie said.  “We hope the Challenge Fund will encourage new support by people who don't know about the work of the foundation and inspire them to get involved. Our goal is to put Damon Runyon on the map as a critically important supporter of the best young scientists in the Bay Area.”

Damon Runyon is committed to ensuring that early career scientists are paired with exceptional mentors so they are empowered to reach their highest potential. In fact, this positive experience has motivated many of our past award recipients to mentor new generations of scientists. We talked with two former Fellows about this important facet of life as a successful scientist: Abby Dernburg, PhD, Howard Hughes Medical Institute Investigator and Professor of Molecular and Cell Biology at UC Berkeley, and Daniel Jarosz, PhD, Assistant Professor of Chemical and Systems Biology and of Developmental Biology at Stanford University.

In its second year, the Innovators in Science Award recognizes research excellence in Regenerative Medicine. Shruti Naik, PhD (Damon Runyon Fellow '14-'17 and Damon Runyon-Dale F. Frey Breakthrough Scientist '17-'19) of New York University, received the Early-Career Scientist Award with a $200,000 grant.

Damon Runyon scientists recently shared some of the cutting-edge cancer therapies that are saving lives at an event sponsored by the Young Presidents’ Organization in New York City. Jedd D. Wolchok, MD, PhD, discussed immunotherapy for melanoma—these drugs harness a patient’s immune system to find and kill cancer cells. Christopher E. Barbieri, MD, PhD, presented his research using therapy to specifically target the damage in prostrate cells that causes cancer. Today, these two approaches play a critical role in treating cancer and providing hope for many patients.

By Lorraine W. Egan, Outgoing President and CEO of Damon Runyon Cancer Research Foundation

Earlier this month, I attended my last meeting of the Damon Runyon Fellowship Award Committee before I retire. Damon Runyon conducts peer review at the highest level with the most respected scientific leaders reviewing the proposals of our applicants to decide if they merit funding.This meeting reaffirmed my strong belief that rigorous peer review works in choosing the best scientists to fund.